Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of sitagliptin + metformin ER versus Janumet XR in healthy Thai adults under fed conditions
TCTR20261023001Phase 1Not yet recruiting
- Sponsor
- Dr. Sasitorn Kittivoravitkul
- Start
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin + metformin, sitagliptin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dr. Sasitorn Kittivoravitkul. Primary endpoints: Maximum plasma concentration (Cmax) at 72.00 hours, Area under the plasma concentration-time curve to last observed concentration (AUC0-t) at 72.00 hours and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
sitagliptin + metforminsitagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20261023001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20261023001.